IRONWOOD PHARMACEUTICALS, INC. Revenues
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Revenues of $69.16 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-04.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2018-05-04
- IRONWOOD PHARMACEUTICALS, INC. revenues for the quarter ending 2018-03-31 was $69.16M, a 32.57% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. revenues for the quarter ending 2017-12-31 was $94.21M, a 7.72% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. revenues for the quarter ending 2017-09-30 was $86.83M, a 31.34% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. revenues for the quarter ending 2017-06-30 was $65.08M, a 19.74% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. revenues for fiscal 2017 was $298.28M, a 8.88% increase from fiscal 2016.
- IRONWOOD PHARMACEUTICALS, INC. revenues for fiscal 2016 was $273.96M, a 83.18% increase from fiscal 2015.
- IRONWOOD PHARMACEUTICALS, INC. revenues for fiscal 2015 was $149.56M, a 95.66% increase from fiscal 2014.
- IRONWOOD PHARMACEUTICALS, INC. revenues for fiscal 2014 was $76.44M, a 234.06% increase from fiscal 2013.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2018-03-31 | $69.16M 10-Q · filed 2018-05-04 | $163.36M derived: sum of 2 quarters · filed 2018-05-04 | $250.19M derived: sum of 3 quarters · filed 2018-05-04 | $315.26M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-12-31 | $94.21M 10-K · filed 2018-02-22 | $181.03M derived: sum of 2 quarters · filed 2018-02-22 | $246.11M derived: sum of 3 quarters · filed 2018-02-22 | $298.28M 10-K · filed 2018-02-22 |
| 2017-09-30 | $86.83M 10-K · filed 2018-02-22 | $151.90M derived: sum of 2 quarters · filed 2018-02-22 | $204.07M 10-Q · filed 2017-11-02 | $291.53M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-06-30 | $65.08M 10-K · filed 2018-02-22 | $117.24M 10-Q · filed 2017-08-03 | $204.70M derived: sum of 3 quarters · filed 2018-05-04 | $270.81M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-03-31 | $52.17M 10-Q · filed 2018-05-04 | $139.63M derived: sum of 2 quarters · filed 2018-05-04 | $205.73M derived: sum of 3 quarters · filed 2018-05-04 | $260.08M derived: sum of 4 quarters · filed 2018-05-04 |
| 2016-12-31 | $87.46M 10-K · filed 2018-02-22 | $153.56M derived: sum of 2 quarters · filed 2018-02-22 | $207.91M derived: sum of 3 quarters · filed 2018-02-22 | $273.96M 10-K · filed 2018-02-22 |
| 2016-09-30 | $66.11M 10-K · filed 2018-02-22 | $120.46M derived: sum of 2 quarters · filed 2018-02-22 | $186.50M 10-Q · filed 2017-11-02 | $239.81M derived: sum of 4 quarters · filed 2018-02-22 |
| 2016-06-30 | $54.35M 10-K · filed 2018-02-22 | $120.39M 10-Q · filed 2017-08-03 | $173.70M derived: sum of 3 quarters · filed 2018-02-22 | $213.27M derived: sum of 4 quarters · filed 2018-02-22 |
| 2016-03-31 | $66.04M 10-K · filed 2018-02-22 | $119.35M derived: sum of 2 quarters · filed 2018-02-22 | $158.92M derived: sum of 3 quarters · filed 2018-02-22 | $186.66M derived: sum of 4 quarters · filed 2018-02-22 |
| 2015-12-31 | $53.31M 10-K · filed 2017-02-22 | $92.88M derived: sum of 2 quarters · filed 2017-02-22 | $120.62M derived: sum of 3 quarters · filed 2017-02-22 | $149.56M 10-K · filed 2018-02-22 |
| 2015-09-30 | $39.57M 10-K · filed 2017-02-22 | $67.32M derived: sum of 2 quarters · filed 2017-02-22 | $96.25M 10-Q · filed 2016-11-07 | $134.32M derived: sum of 4 quarters · filed 2017-02-22 |
| 2015-06-30 | $27.74M 10-K · filed 2017-02-22 | $56.68M 10-Q · filed 2016-08-08 | $94.75M derived: sum of 3 quarters · filed 2017-02-22 | $111.67M derived: sum of 4 quarters · filed 2017-02-22 |
| 2015-03-31 | $28.93M 10-K · filed 2017-02-22 | $67.00M derived: sum of 2 quarters · filed 2017-02-22 | $83.92M derived: sum of 3 quarters · filed 2017-02-22 | $90.76M derived: sum of 4 quarters · filed 2017-02-22 |
| 2014-12-31 | $38.07M 10-K · filed 2016-02-19 | $54.99M derived: sum of 2 quarters · filed 2016-02-19 | $61.83M derived: sum of 3 quarters · filed 2016-02-19 | $76.44M 10-K · filed 2017-02-22 |
| 2014-09-30 | $16.92M 10-K · filed 2016-02-19 | $23.76M derived: sum of 2 quarters · filed 2016-02-19 | $38.36M 10-Q · filed 2015-11-05 | $43.39M derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-06-30 | $6.84M 10-K · filed 2016-02-19 | $21.45M 10-Q · filed 2015-08-07 | $26.48M derived: sum of 3 quarters · filed 2016-02-19 | $31.41M derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-03-31 | $14.61M 10-K · filed 2016-02-19 | $19.64M derived: sum of 2 quarters · filed 2016-02-19 | $24.57M derived: sum of 3 quarters · filed 2016-02-19 | $34.23M derived: sum of 4 quarters · filed 2016-02-19 |
| 2013-12-31 | $5.03M 10-K · filed 2015-02-18 | $9.96M derived: sum of 2 quarters · filed 2015-02-18 | $19.63M derived: sum of 3 quarters · filed 2015-02-18 | $22.88M 10-K · filed 2016-02-19 |
| 2013-09-30 | $4.93M 10-K · filed 2015-02-18 | $14.60M derived: sum of 2 quarters · filed 2015-02-18 | $17.85M 10-Q · filed 2014-11-05 | $44.83M derived: sum of 4 quarters · filed 2015-02-18 |
| 2013-06-30 | $9.66M 10-K · filed 2015-02-18 | $12.92M 10-Q · filed 2014-08-05 | $39.90M derived: sum of 3 quarters · filed 2015-02-18 | $136.31M derived: sum of 4 quarters · filed 2015-02-18 |
| 2013-03-31 | $3.25M 10-K · filed 2015-02-18 | $30.23M derived: sum of 2 quarters · filed 2015-02-18 | $126.65M derived: sum of 3 quarters · filed 2015-02-18 | $141.25M derived: sum of 4 quarters · filed 2015-02-18 |
| 2012-12-31 | $26.98M 10-K · filed 2014-02-07 | $123.39M derived: sum of 2 quarters · filed 2014-02-07 | $138.00M derived: sum of 3 quarters · filed 2014-02-07 | $150.25M 10-K · filed 2015-02-18 |
| 2012-09-30 | $96.41M 10-K · filed 2014-02-07 | $111.02M derived: sum of 2 quarters · filed 2014-02-07 | $123.27M 10-Q · filed 2013-10-28 | $155.42M derived: sum of 4 quarters · filed 2014-02-07 |
| 2012-06-30 | $14.60M 10-K · filed 2014-02-07 | $26.85M 10-Q · filed 2013-08-08 | $59.01M derived: sum of 3 quarters · filed 2014-02-07 | $71.22M derived: sum of 4 quarters · filed 2014-02-07 |
| 2012-03-31 | $12.25M 10-K · filed 2014-02-07 | $44.40M derived: sum of 2 quarters · filed 2014-02-07 | $56.62M derived: sum of 3 quarters · filed 2014-02-07 | $67.88M derived: sum of 4 quarters · filed 2014-02-07 |
| 2011-12-31 | $32.15M 10-K · filed 2013-02-21 | $44.37M derived: sum of 2 quarters · filed 2013-02-21 | $55.63M derived: sum of 3 quarters · filed 2013-02-21 | $65.87M 10-K · filed 2014-02-07 |
| 2011-09-30 | $12.22M 10-K · filed 2013-02-21 | $23.48M derived: sum of 2 quarters · filed 2013-02-21 | $33.72M 10-Q · filed 2012-11-06 | $50.49M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-06-30 | $11.26M 10-K · filed 2013-02-21 | $21.50M 10-Q · filed 2012-08-07 | $38.27M derived: sum of 3 quarters · filed 2013-02-21 | $47.33M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-03-31 | $10.24M 10-K · filed 2013-02-21 | $27.01M derived: sum of 2 quarters · filed 2013-02-21 | $36.07M derived: sum of 3 quarters · filed 2013-02-21 | $45.26M derived: sum of 4 quarters · filed 2013-02-21 |
| 2010-12-31 | $16.77M 10-K · filed 2012-02-29 | $25.83M derived: sum of 2 quarters · filed 2012-02-29 | $35.02M derived: sum of 3 quarters · filed 2012-02-29 | $43.86M 10-K · filed 2013-02-21 |
| 2010-09-30 | $9.06M 10-K · filed 2012-02-29 | $18.25M derived: sum of 2 quarters · filed 2012-02-29 | $27.09M 10-Q · filed 2011-11-09 | |
| 2010-06-30 | $9.19M 10-K · filed 2012-02-29 | $18.03M 10-Q · filed 2011-08-12 | ||
| 2010-03-31 | $8.84M 10-K · filed 2012-02-29 | |||
| 2009-12-31 | $34.32M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |